Leaflet BUGVI 5mg / ml powder for dispersion for infusion


Indicated for: cancer

Route of administration: infusion

Substance: paclitaxel (taxane antineoplastic)

ATC: L01CD01 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes)

Paclitaxel is a chemotherapy agent used in the treatment of various cancers, including breast, ovarian, and lung cancer. It works by inhibiting cell division, stabilizing microtubules, and preventing chromosome separation during mitosis.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as nausea, hair loss, or peripheral neuropathy. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, hair loss, and peripheral neuropathy. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about BUGVI 5mg / ml

  • Substance: paclitaxel
  • Date of last drug list: 01-05-2026
  • Commercial code: W70595001
  • Concentration: 5mg / ml
  • Pharmaceutical form: powder for dispersion for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 1818.82 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: STADA ARZNEIMITTEL AG - AUSTRIA
  • Holder: STADA M&D S.R.L. - ROMANIA
  • Number: 15619/2024/01
  • Shelf life: 3 years-after packing for marketing;Dupa reconstituire - it is used immediately

Concentrations available for paclitaxel

  • 5mg/ml
  • 6mg/ml

Compensation lists for BUGVI 5mg / ml STADA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

1818.82 RON

938.53 RON

880.29 RON